Considering the 8.7‐fold difference of the antiproliferative effect of SCR‐7952 and AG‐270 on HCT116 MTAP−/− cancer cells (34.4 vs. 300.4 nM), the significantly lower therapeutic dosage of SCR‐7952 was reasonable. The gene discussed is MTAP; the disease is cancer.